ST segment elevation in the right precordial leads following administration of class Ic antiarrhythmic drugs. Issue 1 (1st January 2001)

• Record Type: Journal Article
• Authors: Yasuda, M; Nakazato, Y; Yamashita, H; Sekita, G; Kawano, Y; Mineda, Y; Nakazato, K; Tokano, T; Sumiyoshi, M; Nakata, Y
• Is Part Of: Heart. Volume 85:Issue 1(2001)
• Page Start: e3
• Page End: e3
• Publication Date: 2001-01-01
• Subjects: class Ic antiarrhythmic drugs -- Brugada syndrome -- ST segment elevation; Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/heart.85.1.e3
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Electrocardiographic changes were evaluated retrospectively in five patients without previous episodes of syncope or ventricular fibrillation who developed abnormal ST segment elevation mimicking the Brugada syndrome in leads V1–V3 after the administration of class Ic antiarrhythmic drugs. Pilsicainide (four patients) or flecainide (one patient) were administered orally for the treatment of symptomatic paroxysmal atrial fibrillation or premature atrial contractions. The QRS duration, QTc, and JT intervals on 12 lead surface ECG before administration of these drugs were all within normal range. After administration of the drugs, coved-type ST segment elevation in the right precordial leads was observed with mild QRS prolongation, but there were no apparent changes in JT intervals. No serious arrhythmias were observed during the follow up periods. Since ST segment elevation with mild QRS prolongation was observed with both pilsicainide and flecainide, strong sodium channel blocking effects in the depolarisation may have been the main factors responsible for the ECG changes. As the relation between ST segment elevation and the incidence of serious arrhythmias has not yet been sufficiently clarified, electrocardiographic changes should be closely monitored whenever class Ic drugs are given.